series-a
Stage
4
Investors
About
Tagomics develops a proprietary multiomic platform that combines genomics, epigenomics, and fragmentomics to unlock disease-associated biomarkers from biological sources, enabling more comprehensive insights into diseases such as cancer for improved diagnosis and treatment.
Explore Tagomics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.